Can TMAO activate inflammatory signaling and increase cytokine production?

TMAO (trimethylamine N-oxide) has experimentally demonstrated pro-inflammatory effects in innate immune and endothelial cells. The evidence supports a mechanistic capacity to increase inflammatory cytokine production, but does not establish that circulating TMAO causes systemic inflammation in humans.

Experimental inflammatory evidence

• In mouse and bone-marrow-derived macrophage models, TMAO promoted M1-associated inflammatory responses and increased IL-1β, with IL-6 and TNF-α increases in some settings.
• In LPS-primed macrophages, TMAO increased IL-1β and IL-18 in a dose-dependent manner. TNF-α was not increased in that model, indicating that cytokine effects depend on cellular context and priming state.
• Human aortic endothelial-cell studies found activation of MAPK/ERK and NF-κB signaling, increased nuclear localization of NF-κB p65, and induction of IL-6, COX-2, and endothelial adhesion molecules. NF-κB inhibition reduced inflammatory responses and leukocyte adhesion.

Mechanistic findings

• A central supported mechanism is NLRP3 inflammasome activation. TMAO increased NLRP3/ASC association and caspase-1 activity in macrophages and HUVECs, leading to processing and release of IL-1β; IL-18 was also increased in primed macrophages.
• Pharmacologic inhibition of NLRP3 or caspase-1, and genetic Nlrp3 deletion, attenuated TMAO-associated cytokine responses, supporting an NLRP3-dependent pathway.
• Endothelial findings additionally implicate mitochondrial reactive oxygen species, ICAM-1, and MMP-9, with transcriptomic data suggesting that exposure duration may influence the response.

Clinical interpretation

• These findings are mechanistically coherent but remain restricted to cell and animal systems. Human causal relevance, clinically comparable exposure levels, and dose–response relationships are not established.
• Renal function is an important confounder: in an older-adult cohort, the association between TMAO and incident ASCVD weakened after adjustment for eGFR.

Bottom line

• TMAO can activate macrophage and endothelial inflammatory signaling and increase cytokines—particularly IL-1β, IL-18, and IL-6—in experimental models, principally through NLRP3 inflammasome, NF-κB, and MAPK/ERK pathways. Translation to human inflammatory risk remains uncertain.